NEWS Tetra Bio-Pharma Inc .: Rx Princeps (TM) Now Available for Patients Through Aphria Authorized Production Partner
November 16, 2017
OTTAWA, ONTARIO- (Marketwired - November 16, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP) (OTCQB: TBPMF), a global leader in the development and discovery of cannabinoid-based drugs, today announced that Rx Princeps (TM), a unique blend of dried medical cannabis used in its PPP001 clinical trials, is now available through licensed producer Aphria Inc. ("Aphria") under the Cannabis Medical Access Regulations (CPRA).
Based on the most recent CPMA Canada market data, sales of dried medical cannabis Canada from April 2017 to March 2018 are estimated to be $ 188 million; Tetra is now entering this lucrative market and plans to gradually acquire a significant share over the next two years. Mr. Fortier, CEO of Tetra, said last week "We expect to generate around $ 1.5 million in sales in fiscal 2018 in our initial launch." Through our promotion and education efforts in Quebec, In New Brunswick and part of Ontario, we estimate that more than eight thousand patients will begin using Rx Princeps (TM) under the prescription of their doctors over the next twelve months. "
Rx Princeps (TM) is a new option for doctors who want to prescribe medical cannabis. Rx Princeps (TM) Prescription with Rx Princeps (TM) Inhalation Device Allows Patients to Maximize the Benefits of Medical Cannabis with a Fixed Dose of Product, Ensuring Consistent Treatment with a standardized product of high quality.
Aphriacultive and medical cannabis product as part of a strict quality management program. Tetra chose Aphria as a partner because their production processes were adopted by the highly regulated and limited pharmaceutical industry, and go beyond the regulation of the cannabis industry mandated by Health Canada. Therefore, Aphria products meet the stringent quality standards that Tetra sets for the medical community and its patients.
200,000 patients are already enrolled in the ACMPR program and approximately 1.5 million Canadian adults suffer from chronic pain and are considered non-responders to opioids; Medical cannabis may be a new therapeutic choice for these patients, but doctors need bioavailability and safety data to prescribe medical cannabis with confidence. According to Health Canada Less than 3,000 doctors actually prescribe cannabis to their patients. Tetra is committed to providing them with rigorous data on safety and bioavailability. Tetra began educating pain clinics and the medical profession across Canada about Rx Princeps (TM), including its benefits for patients.
In Quebec, Tetra works closely with Sante Cannabis to educate patients and support them in their medical journey with cannabis. Health Cannabis is the first cannabinoids clinic and medical marijuana resource center in Quebec.